Making Care More Affordable for People Facing Chronic Conditions

New program for people living with obesity and psoriasis (PsO) or psoriatic arthritis (PsA) builds on our longstanding leadership in access and affordability

For people living with chronic conditions like diabetes, obesity, and autoimmune diseases, effective treatments can make a significant impact on managing their health. Yet, many patients face barriers to accessing the medicines they need, which can impact their ability to effectively manage these diseases. These challenges can be even greater for those managing multiple chronic conditions, an issue affecting a growing number of people. According to the CDC, more than a quarter of American adults live with two or more chronic conditions,¹ making medicine affordability a critical concern.

As a medicines company, we recognize our responsibility to make treatments more accessible. We have a long history of pioneering affordability initiatives, from capping insulin costs to offering best-in-class savings programs. We continue to introduce new strategies to support millions of people living with obesity and autoimmune conditions. For example, through our latest program, eligible, commercially insured patients who are prescribed our medicines for both obesity and psoriasis (PsO) or psoriatic arthritis (PsA) may be able to pay as little as $30 per month for both treatments. Learn more here.

People living with chronic diseases deserve access to the medicines they need to live healthier lives, and we're working to close the gaps in the U.S. health care system that can prevent that from happening. While introducing new affordability solutions is another step forward, it is only part of the answer. We call on policymakers, insurers, pharmacy benefit managers, and employers to collaborate on long-term solutions that improve access to essential medicines, so patients can better manage their chronic conditions.

Reference

^1. Boersma P, Black LI, Ward BW. Prevalence of Multiple Chronic Conditions Among US Adults, 2018. Prev Chronic Dis 2020;17:200130. DOI: http://dx.doi.org/10.5888/pcd17.200130